HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+23.31%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$2.39B
AUM Growth
+$2.39B
(+2.6%)
Cap. Flow
-$369M
Cap. Flow
% of AUM
-15.47%
Top 10 Holdings %
Top 10 Hldgs %
46.51%
Holding
67
New
22
Increased
12
Reduced
15
Closed
17
Top Buys
| 1 |
Becton Dickinson
BDX
|
$121M |
| 2 |
Cigna
CI
|
$88.6M |
| 3 |
AbbVie
ABBV
|
$83.8M |
| 4 |
Danaher
DHR
|
$66.6M |
| 5 |
Amgen
AMGN
|
$61.1M |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$145M |
| 2 |
Haemonetics
HAE
|
$143M |
| 3 |
Teleflex
TFX
|
$119M |
| 4 |
Labcorp
LH
|
$87.3M |
| 5 |
Charles River Laboratories
CRL
|
$84.4M |
Sector Composition
| 1 | Healthcare | 99.83% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Aurinia Pharmaceuticals
AUPH
$1.58B
| $154M | 6.47% | 9,501,398 -262,522 | -3% | -$4.27M |
|
|
2
Becton Dickinson
BDX
$55.3B
| $145M | 6.08% | 606,470 +506,470 | +506% | +$121M |
|
3
Madrigal Pharmaceuticals
MDGL
$9.76B
| $136M | 5.68% | 1,197,884 -204,366 | -15% | -$23.1M |
|
|
4
AbbVie
ABBV
$372B
| $129M | 5.42% | 1,317,570 +853,670 | +184% | +$83.8M |
|
|
NVRO
5
DELISTED
NEVRO CORP.
NVRO
| $126M | 5.28% | 1,054,103 -698,517 | -40% | -$83.5M |
|
|
6
Labcorp
LH
$23.1B
| $92M | 3.86% | 554,010 -525,716 | -49% | -$87.3M |
|
|
7
Cigna
CI
$80.3B
| $88.6M | 3.71% | +472,360 | New | +$88.6M |
|
8
Medtronic
MDT
$119B
| $83.9M | 3.52% | 915,440 +582,110 | +175% | +$53.4M |
|
9
HCA Healthcare
HCA
$94.5B
| $77.8M | 3.26% | 801,290 +571,560 | +249% | +$55.5M |
|
10
IQVIA
IQV
$32.4B
| $77.3M | 3.24% | 544,790 +66,210 | +14% | +$9.39M |
|
11
Encompass Health
EHC
$12.3B
| $77.2M | 3.23% | 1,246,419 -279,390 | -18% | -$17.3M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $74.8M | 3.13% | 666,510 +518,240 | +350% | +$58.2M |
|
13
LivaNova
LIVN
$3.08B
| $69.6M | 2.91% | 1,445,500 +219,610 | +18% | +$10.6M |
|
14
UnitedHealth
UNH
$281B
| $67.7M | 2.84% | 229,650 +58,820 | +34% | +$17.3M |
|
|
15
Danaher
DHR
$147B
| $66.6M | 2.79% | +376,665 | New | +$66.6M |
|
16
Bristol-Myers Squibb
BMY
$96B
| $62.5M | 2.62% | 1,062,500 +888,140 | +509% | +$52.2M |
|
|
17
Amgen
AMGN
$155B
| $61.1M | 2.56% | +259,200 | New | +$61.1M |
|
18
Abbott
ABT
$231B
| $58.3M | 2.44% | +638,180 | New | +$58.3M |
|
19
Guardant Health
GH
$8.41B
| $58.3M | 2.44% | +718,840 | New | +$58.3M |
|
|
BPMC
20
DELISTED
Blueprint Medicines
BPMC
| $58M | 2.43% | 743,018 -537,352 | -42% | -$41.9M |
|
21
Pediatrix Medical
MD
$1.5B
| $57.9M | 2.43% | 3,387,965 +741,765 | +28% | +$12.7M |
|
22
Thermo Fisher Scientific
TMO
$186B
| $55.1M | 2.31% | 152,180 +92,180 | +154% | +$33.4M |
|
|
NUVA
23
DELISTED
NuVasive, Inc.
NUVA
| $54M | 2.26% | +969,580 | New | +$54M |
|
24
Acadia Pharmaceuticals
ACAD
$4.38B
| $49.7M | 2.08% | 1,025,000 -1,205,474 | -54% | -$58.4M |
|
25
Royalty Pharma
RPRX
$15.6B
| $44.5M | 1.86% | +916,350 | New | +$44.5M |
|